DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Duoneb is a drug marketed by Mylan Speciality Lp and is included in one NDA. There is one patent protecting this drug.
This drug has fifteen patent family members in eight countries.
The generic ingredient in DUONEB is albuterol sulfate; ipratropium bromide. There are thirty-eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the albuterol sulfate; ipratropium bromide profile page.
There is one tentative approval for the generic drug (albuterol sulfate; ipratropium bromide), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
Recent Clinical Trials for DUONEB
Identify potential brand extensions & 505(b)(2) entrants
|University Hospitals Cleveland Medical Center||Phase 1|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Mylan Speciality Lp||DUONEB||albuterol sulfate; ipratropium bromide||SOLUTION;INHALATION||020950-001||Mar 21, 2001||DISCN||Yes||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|